Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
DALLAS, October 29, 2013 /PRNewswire/ --
The "Immunoassay Market[Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Applications (Infectious Diseases, Cancer, Endocrinology, Cardiology), End Users (Hospitals, Laboratory, Academics)] - Global Forecast to 2018", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global immunoassays market along with the estimates and forecasts of the revenue and share analysis.
Browse 118 market data tables with 86 figures spread through 421 pages and in-depth TOC on "Immunoassay Market [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Applications (Infectious Diseases, Cancer, Endocrinology, Cardiology), End Users (Hospitals, Laboratory, Academics)] - Global Forecast to 2018".
Early buyers will receive 10% customization on this report.
The global Immunoassays Market is segmented by technology, application, product (analyzers and reagents), and end user. The global Immunoassays Market, by technology, is further segmented into enzyme immunoassays, fluorescent immunoassays, chemiluminescence immunoassays, radioimmunoassays, and others. Enzyme immunoassays accounted for the largest share of the global immunoassays market in 2012, owing to their long-term presence and high sensitivity. However, the chemiluminescence Immunoassays Market will see the highest growth in the next five years, which is attributed to the high-throughput and automation offered by CLIAs.
On the basis of application, the Immunoassays Market has segments like oncology, infectious diseases, cardiology, bone and mineral, endocrinology, autoimmunity, toxicology, hematology (anemia), neonatal screening, and others. The infectious diseases segment commanded the largest share of 35.2% of the Immunoassays Market in 2012 due to the high specificity of immunoassays in diagnosing these diseases. Oncology will be the fastest-growing application owing to the high prevalence of cancer diseases worldwide and the development of a wide array of cancer biomarkers.
The Americas is the largest revenue generator for immunoassays, followed by Europe. Both markets have reached their maturity phase of growth and are estimated to register mid single-digit growth rates for the next five years. Asia-Pacific and LATAM are also expected to grow at a rapid pace during the analysis period owing to the urbanization, huge investment opportunities in these Immature Markets, and the growing numbers of diagnostic laboratories in these regions. The growth of the Immunoassays Market will mainly be driven by countries like China and India that provide a large population base for companies. Moreover, increasing healthcare spending and government initiatives will propel the Immunoassays Market in these countries.
The immunoassays segment contributes about one-fourth to the IVD market and is valued at $13.0 billion in 2013. Immunoassays are characterized by high specificity, sensitivity, and low costs. It is estimated to be the second-fastest growing sector of IVD after molecular diagnostics. The Immunoassays Market will be driven by factors such as growing incidences of chronic and infectious diseases, increasing aging population, ongoing technological innovations, increasing demand for non-invasive diagnostic tools and techniques, and the identification and introduction of novel biomarkers. The availability of novel tests based on condition-specific markers and increasing adoption of immunoassay tests in emerging countries are also factors that exhibit growth opportunities for the Immunoassays Market. There is also an increasing demand for Lateral flow (LF) tests due to the need for immediate medical information and the demand for rapid test results, easy and convenient access, accuracy, and sensitivity. Thus LF tests are driving the Immunoassays Market.
On the other hand, factors such as the increasing commoditization of certain immunoassays, stringent regulatory approvals, increasing pricing pressures on leading players, and reduction in healthcare budget will restrict the growth of the market.
Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Ortho Clinical Diagnostics (U.S.), Alere, Inc. (U.S.), Sysmex Corporation (Japan), and DiaSorin S.P.A. (Italy) are the key industry participants. The Immunoassays Market is dominated by established players and is consolidated, with the top 5 players occupying more than 80% of the market. The market offers huge barriers for new entrants as the industry demands high capital investments for R&D and testing and manufacturing of products. Moreover, companies have to follow stringent regulations to get product approvals in various countries.
Browse related reports
In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] - Forecast To 2017
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, agriculture industry, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
As it's been doing every year since 1955, the North American Aerospace Defense Command, better known as NORAD, will be tracking Santa's progress on Christmas Eve.More >>
As it's been doing every year since 1955, the North American Aerospace Defense Command, better known as NORAD, will be tracking Santa's progress on Christmas Eve as he makes his way around the world delivering gifts, eating mince pies, and knocking back copious amounts of sherry.More >>
The upcoming holiday is not just about the parades, football games, or all the turkey you can eat. It's about spending time with friends and loved ones and having fun, in real life rather than on the Web.More >>
The upcoming holiday is not just about the parades, football games, or all the turkey you can eat. It's about spending time with friends and loved ones and having fun, in real life rather than on the Web. More >>
Most of us don't like being in front of the camera because the self-conscious side of us says we're not attractive enough to be in photos.More >>
Most of us don't like being in front of the camera because the self-conscious side of us says we're not attractive enough to be in photos. Well, portrait photographer Peter Hurley tells us that we are all beautiful people but the secret to looking really photogenic is through something he dubbed the "Squinch." More >>